No Patient Left Behind

No Patient Left Behind

@nplb.bsky.social

We're a non-profit dedicated to making innovative medications affordable for everyone in America.

96 followers34 following20 posts

No Patient Left Behind
@nplb.bsky.social

It is awful that Independence BCBS (IBX) health plan thinks its ok to force patients to wait 18 months after @fda.gov accelerated approval to cover a treatment. 📝Please sign the Little Hercules Foundation letter urging IBX to reverse policy docs.google.com/forms/d/e/1F... @govmurphy.bsky.social

docs.google.comCommunity Sign On Letter - IBX policy excluding coverage for rare disease products approved through Accelerated ApprovalAs organizations representing the rare disease community, we are very concerned about Independence Blue Cross Blue Shield’s (IBX) policy (08.02.35) that excludes coverage for FDA-approved rare disease...
No Patient Left Behind
@nplb.bsky.social

#IRA’s small molecule penalty disproportionately harms early-stage drug development and has far greater harmful impact on innovation & patients than previously recognized. #CBO should incorporate real-world insights from specialist investors into its models. link.springer.com/article/10.1...

link.springer.comThe Impact of the Inflation Reduction Act on Investment in Innovative Medicines: A Project-Level Analysis - Therapeutic Innovation & Regulatory ScienceThe impact of Medicare’s price negotiation on long-term pharmaceutical innovation and patient welfare remains one of the most widely debated topics across stakeholder groups. Existing policy simulatio...
No Patient Left Behind
@nplb.bsky.social

We released new research with Charles River Associates that highlights a growing concern among #Medicare beneficiaries—many want lower out-of-pocket prescription costs but fear that new policies under the IRA will make it harder to get the medicines they need. 🧵 (1/4)

View full thread
No Patient Left Behind
@nplb.bsky.social

Patients want policies that lower their out-of-pocket costs without restricting access to the treatments they are prescribed—let’s listen to them. Read the full findings here: (4/4)

nopatientleftbehind.orgPrice Controls Hinder Treatment Access in Medicare Part D — No Patient Left BehindA new survey demonstrates that a majority of consumers want health plans to lower out-of- pocket costs, but are concerned state government price controls will harm access and not reduce costs
No Patient Left Behind
@nplb.bsky.social

We released new research with Charles River Associates that highlights a growing concern among #Medicare beneficiaries—many want lower out-of-pocket prescription costs but fear that new policies under the IRA will make it harder to get the medicines they need. 🧵 (1/4)

No Patient Left Behind
@nplb.bsky.social

Of all respondents: 🚫 30% said their insurance denied them a doctor-prescribed drug in the past year, and 17% got no treatment at all. 💊 81% worry that the IRA will force them to switch from their prescribed medications. 💰 92% expect their out-of-pocket costs to increase. (2/4)

No Patient Left Behind
@nplb.bsky.social

Autoimmune diseases afflict 45 million Americans—and it requires a collective community effort to change that. Our new Community Quest video shows how investors, innovators, regulators, patients, insurers—and you—make new treatments possible, accessible, and affordable.

nopatientleftbehind.orgOur Quest to Beat Autoimmune Disorders — No Patient Left BehindBiomedical innovators are developing new autoimmune therapeutics - insurance reform will ensure new treatments and cures are accessible and affordable.
No Patient Left Behind
@nplb.bsky.social

Other wealthy nations continue to undervalue the impact of life-saving medicines, paying far less for them while still benefiting from our scientific breakthroughs. These other wealthy countries, our trade competitors, don't have true markets for medicines.

No Patient Left Behind
@nplb.bsky.social

Nuts. ⁦@wsjwernau.bsky.social “Health plans process more than 5 billion claims annually. @kff.org says ~850M are denied. Less than 1% of patients appeal.” ⁦Still time for CMS ⁩to fix prior auth rules to better protect patients in time for ‘26 plan year. www.wsj.com/health/healt...

wsj.comHealth Insurers Deny 850 Million Claims a Year. The Few Who Appeal Often Win.Patients who contest denials face a daunting process, but many are successful. “This appeal saved my life.”
No Patient Left Behind
@nplb.bsky.social

.@miafarrow.bsky.social Thank you for highlighting!! Please consider adding your name in support of merit-based, government-supported basic research. U.S. biomedical research leadership thrives on stability, transparency and long-term commitment. nopatientleftbehind.org/defending-th...

nopatientleftbehind.orgDefending the NIH, the NSF and the foundation of American science — No Patient Left Behind
Mia Farrow@miafarrow.bsky.social

NIH has cut billions of dollars in biomedical funding, effective immediately The move halts a large slice of money for most universities and research institutions virtually overnight, imperiling vital research in everything from cancer to heart disease. www.washingtonpost.com/health/2025/...

washingtonpost.comNIH cuts billions of dollars in biomedical funding, effective immediatelyThe move halts a large slice of money for most universities and research institutions virtually overnight, imperiling vital research in everything from cancer to heart disease.
No Patient Left Behind
@nplb.bsky.social

Health economists, patient advocates, and industry leaders at #ISPOREurope met to enjoy tapas and discuss the latest research at an NPLB networking reception. It was great to connect with conference attendees and demonstrate an early version of our upcoming GCEA calculator.

You are up to date.